Article thumbnail

Fibrolamellar hepatocellular carcinoma: Exploring molecular mechanisms and differentiation pathways to better understand disease outcomes and prognosis

By Cassandra A. Kersten, Elise N. Sloey, Eric Zhou, Ying Peng, Michael S. Torbenson and Yi Guo


Fibrolamellar hepatocellular carcinoma (FLC) is a rare but aggressive liver cancer of children that occurs predominantly in teenagers without a history of liver disease. Surgical resection remains the only therapeutic option, and the recurrence rate is extremely high (>50% within 3 years). A newly discovered chromosomal deletion that occurs in the majority of FLCs generates a novel kinase fusion between DnaJ heat shock protein family member B1 (DNAJB1) and protein kinase cAMP-activated catalytic subunit alpha (PRKACA) (DNAJB1-PRKACA). Despite its high penetrance and apparent specificity for FLC, the oncogenic role of this fusion event remains unclear. In this review article, we discuss the histology, presentation and diagnosis, current treatment, and roles of the DNAJB1-PRKACA as well as research models contributing to our understanding of this disease. Keywords: Fibrolamellar hepatocellular carcinoma (FLC), DnaJ heat shock protein family member B1 (DNAJB1), Protein kinase cAMP-activated catalytic subunit alpha (PRKACA), Pediatric cancer, Liver cance

Topics: Diseases of the digestive system. Gastroenterology, RC799-869
Publisher: KeAi Communications Co. Ltd.
Year: 2017
DOI identifier: 10.1016/j.livres.2017.12.003
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.